- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04245683
Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Standards of care for patients with rectal cancer are evolving over time. Surgery for rectal cancer is associated with significant short- and long-term side effects for patients, including changes in bowel function, self-image, ability to work, and sexual function. Emerging data indicates that some patients experiencing complete clinical response to neoadjuvant therapy (treatment given prior to surgery) may be able to forego surgery, without compromising cancer outcomes. Current National Cancer Center Network (NCCN) guidelines for the treatment of rectal cancer states that, "...the panel believes that a non-operative management approach may be considered in centers with experienced multi-disciplinary teams, after a careful discussion with the patient of his or her risk tolerance." Between 15-27% of patients achieve a complete pathological response after chemoradiotherapy (CRT), which is administered before surgery, and have low rates of local recurrence and high rates of overall survival. Treating these patients without surgery has been a focus in recent years. Supporting data is mainly from large academic institutions, which have pioneered the approach. There is very little data on this approach in rural populations. While this approach is not considered to represent the standard of care, increasing numbers of patients are choosing to pursue it. It would be useful to accumulate data on treatment of rectal cancer in a rural setting.
The study will collect and analyze data on patient preference for operative versus non-operative management, as well as patient adherence to the careful surveillance regimen required for those electing nonoperative management. In addition, patient outcomes with a focus on quality of life, as measured on a standardized tool at multiple points before, during, and after treatment will be analyzed.
Patients will undergo an initial staging evaluation, regardless of study consent, to include:
- Physical examination
- Endoscopy
- CEA, CBC, CMP
- Pelvic MRI +/- IV contrast preferred, or if MRI contraindicated, endoscopic ultrasound
- CT Chest/Abdomen/Pelvis
Patients will also complete the following survey assessments at the time of study consent:
- Pain Assessment
- QOL- CR29
- QOL- C30
- QOL- Patient Satisfaction Survey
Patients with potentially resectable, newly diagnosed, rectal cancer will receive one of three treatment protocols based on patient and physician preference. These treatment options are considered normal standard of care and are available to all patients regardless of study participation.
Treatment choices are:
- 5-Fluorouracil or Capecitabine with radiotherapy for 6 weeks, followed by a break of 8-12 weeks. Patients who elect this treatment plan will be reevaluated/restaged as described below, then will receive an additional 18 weeks of chemotherapy. Depending on the patient's decision regarding surgery, chemotherapy will be initiated either 4 weeks post-operatively or immediately after restaging for patients electing to forgo surgery.
- Total Neoadjuvant Therapy (TNT) option 1: 6 cycles of Leucovorin Calcium, Fluorouracil, and Oxaliplatin (FOLFOX) over 12 weeks, followed by 6 weeks 5-Fluorouracil or Capecitabine with radiation, then a break of 10-12 weeks 3. TNT option 2: 6 weeks 5-Fluorouracil or Capecitabine with radiation, followed by 6 cycles of FOLFOX over 12 weeks, then a break of 10-12 weeks.
Patients will be monitored throughout their treatments. Treatment will be held at the discretion of the medical oncologist or radiation oncologist for severe skin reactions, severe diarrhea, severe urinary difficulty, admission to the hospital, and neutropenia with or without fever. At the completion of neoadjuvant therapy, there will be a 10-12 week observation period to allow for healing and resolution of inflammation. Patients who do not complete neoadjuvant therapy will be removed from the study. Patients who do complete neoadjuvant therapy will then undergo evaluation of their response using the modalities listed below: Physical Examination Endoscopy CEA Pelvic MRI +/- IV contrast or EUS Biopsy at surgeons discretion of residual mucosal abnormalities
Patients who do not achieve a complete tumor response would not be eligible for non-surgical management, but would continue to be followed for survival.
Those achieving complete tumor responses, as defined by no evidence of tumor on physical examination, endoscopy, MRI, and with a normal CEA value, will then have further discussion with their treating physicians regarding operative vs. non-operative management. The choice of operative or non-operative management will be left to the discretion of the physicians and the patient. Patients will also be presented at the Multidisciplinary Tumor Board to receive input on care.
After patients have been restaged, but prior to any further treatment, the following survey assessments will occur:
- Pain Assessment
- QOL- CR29
- QOL- C30
- QOL- Patient Satisfaction Survey
Operative patients will undergo surgery. They will then either complete their chemotherapy treatment if the patient has not already done so, or go directly to surveillance. Patients will be followed by surveillance for a total of 5 years post operatively. Patients will have CT imaging of the chest/abdomen/pelvis every 6-12 months for 5 years following resection, per NCCN guidelines for patients with stage II or stage III rectal cancer.
Per NCCN guidelines, non-operative patients will either complete their chemotherapy treatment if the patient has not already done so, or go directly to surveillance. Surveillance will consist of having CEA, endoscopy, and imaging (CT scans and MRI) every 3 months for 1 year; then CEA and endoscopy every 3 months with imaging (CT scans and MRI) every 6 months for the next 2 years; and then CEA and endoscopy every 6 months with imaging (CT scans and MRI) every year for 2 years.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Katelyn Tessier
- Phone Number: 607-547-3073
- Email: kately.tessier@bassett.org
Study Locations
-
-
New York
-
Cooperstown, New York, United States, 13326
- Recruiting
- Bassett Healthcare Network
-
Contact:
- Katelyn Tessier
- Phone Number: 607-547-3073
- Email: katelyn.tessier@bassett.org
-
Principal Investigator:
- Eric Bravin, MD
-
Sub-Investigator:
- Raul Monzon, MD
-
Sub-Investigator:
- Luis Oceguera, MD
-
Sub-Investigator:
- Marcy Canary, MD
-
Sub-Investigator:
- Bharatsinh Gharia, MD
-
Sub-Investigator:
- Bryan Lee, DO
-
Sub-Investigator:
- James Leonardo, MD
-
Sub-Investigator:
- Anush Patel, MD
-
Sub-Investigator:
- Timothy Korytko, MD
-
Sub-Investigator:
- Julia Manzerova, MD
-
Sub-Investigator:
- Alfred Tinger, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
For a patient to be considered eligible for this study, ALL of the following conditions must be met:
- Age 18 or greater
- ECOG PS 0-2
- Stage II or III, newly diagnosed, biopsy proven, rectal cancer
- No prior treatment for rectal cancer
- No prior pelvic radiotherapy
- Willing to undergo study related testing and monitoring after treatment
- Women of childbearing potential must rule out pregnancy within 2 weeks prior to registration with a blood test or urine study
- Women must not be pregnant or breastfeeding
- Able to provide informed consent
Exclusion Criteria:
Patients are NOT considered eligible for this study if any of the following conditions apply:
- Patients with metastatic disease
- Patients that are not candidates for surgery
- Patients that refuse neoadjuvant treatment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Operative Group
Patients who select operative treatment and follow up after successful neoadjuvant treatment.
|
surgical removal of the portion of the rectum where the tumor was originally identified
|
Non-operative Group
Patients who select non-operative follow up after successful neoadjuvant treatment
|
patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
patient preferences for operative vs. non-operative management of rectal cancer
Time Frame: 8 months
|
Number of eligible patients who select operative versus non-operative management after successfully completing approximately 20 weeks of neoadjuvant treatment and the 10-12 week post treatment observation period
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient adherence to surveillance protocols
Time Frame: 5 years
|
Percentage of patients who choose non-operative management who successfully comply with the post-neoadjuvant treatment surveillance protocol
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Bravin, MD, Bassett Healthcare
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1526939
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
Clinical Trials on Bowel/rectal resection
-
National Cancer Center, KoreaUnknownRectal CancerKorea, Republic of
-
The Hospital of VestfoldVestre Viken Hospital Trust; Ullevaal University Hospital; Oslo University Hospital and other collaboratorsRecruitingQuality of Life | Rectal Cancer | Ileostomy; Complications | Complication,PostoperativeNorway
-
Fujian Medical UniversityZhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Peking Union... and other collaboratorsActive, not recruiting
-
The University of Hong KongUnknownAdenocarcinoma | Rectal CancerHong Kong
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedColorectal CancerUnited States, Canada
-
Binh Dan HospitalCompleted
-
Campus Bio-Medico UniversityCompletedSurgery | Surgery--Complications | Rectal Tumor | Neoadjuvant Chemoradiotherapy
-
Moroccan Society of SurgeryCompletedRectal NeoplasmsMorocco, Algeria
-
Technische Universität DresdenRecruiting
-
University of PadovaIstituto Oncologico Veneto IRCCS; Azienda Ulss 2 Marca Trevigiana; Associazione... and other collaboratorsRecruitingRectal Cancer Stage T1-T2 | Rectal Cancer Nodal MetastasisItaly